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Abstract
Molecular pathways that control the specification, migration, and number of available smooth
muscle progenitor cells play key roles in determining blood vessel size and structure, capacity for
tissue repair and remodeling, and progression of age-related disorders. Defects in these pathways
will produce malformations of developing blood vessels, depletion of SMC progenitor pools for
vessel wall maintenance and repair, and aberrant activation of alternative differentiation pathways
in vascular disease. A better understanding of the molecular mechanisms that uniquely specify and
maintain vascular SMC precursors is essential if we are to utilize advances in stem and progenitor
cell biology and somatic cell reprogramming for applications directed to the vessel wall.
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Introduction
Advances in reprogramming of differentiated adult somatic cells have focused renewed
attention on molecular pathways that specify lineage- and cell type-specific progenitor
cells 1,2,3. Multiple sources of vascular SMC progenitor cells in embryos have been
identified by fate mapping studies thereby allowing for experimental analysis of the
mechanisms that uniquely specify these progenitors for a smooth muscle fate 4,5. Moreover,
recognition that resident SMC progenitor cells are maintained in adult vessel wall raises
important new questions about the roles they play in vascular repair, remodeling and
disease 6,7,8,9.
Elucidation of molecular pathways that control cell fate decisions within SMC lineages is of
fundamental importance at a basic level. It is also important as a basis for development of
progenitor cell therapies applied to the vessel wall. Vascular SMC differentiation in
embryonic development is recognized by the appearance of cytoskeletal and contractile
protein isoforms, including SMα-actin (Acta2), SM-calponin (Cnn1), and SM-myosin heavy
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chain (Myh11), that confer a functional smooth muscle contractile phenotype on these
cells 10,11,12. No such well-characterized markers are available for identification of SMC
progenitors per se that, by definition, are specified for a smooth muscle fate, but do not
express differentiated SMC marker proteins. In the absence of established markers that
would selectively identify SMC progenitor cells, we recognize these cells by their ability to
differentiate to SMCs in vitro or in vivo. However, as discussed further below, misuse of
SMC markers and particularly the reliance on SMα-actin (Acta2) expression as a sole
criterion for differentiation of a progenitor cell into a SMC is problematic and can lead to
the false conclusion that the progenitor cell type being studied has the capacity to produce
functional SMCs.
Phenotype Plasticity of Vascular Smooth Muscle
Since the earliest ultrastructural studies of smooth muscle tissue, it has been apparent that
SMCs exhibit a wide range of phenotypic variation 13,14,15,16,17. In fact, this diversity was
considered for many years to be evidence of not one but two different cell types in the tunica
media of artery walls, one for contraction and another for synthesis of extracellular matrix
(ECM) proteins 18. In 1979, Chamley-Campbell et al 19 proposed that these two principle
functions of arterial medial cells in vivo, ECM synthesis and agonist-induced contraction,
were embodied in different but interconvertible “synthetic” and “contractile” SMC
phenotypes. SMCs adapted to growth in cell culture, as well as SMCs in developing
embryonic vessels and proliferating at sites of vascular injury, exhibit a synthetic phenotype,
whereas fully differentiated SMCs in mature adult vessels display a contractile
phenotype 16,19. This variation was initially referred to as SMC phenotypic modulation 19,20.
More recently the term SMC phenotypic switching has come into common use to describe
this reversible transition 11. It is important to realize that the two SMC phenotypes share
considerable overlap and that contractile cells can replicate and synthetic cells can possess
contractile filaments.
Transcriptional Control of Smooth Muscle Differentiation
Analysis of the requirements for transcription of SMC marker genes, including SMα-actin
(Acta2), SM22α (Tagln), SM-calponin (Cnn1), and SM-myosin heavy chain (Myh11), in
differentiated SMCs revealed the importance of interactions of serum response factor (SRF;
srf), a MADS box-containing DNA binding protein, with a DNA sequence (CC(AT)6GG)
known as a CArG box 21,22,23,24. The central MADS domain of SRF (Srf) provides a highly
conserved molecular platform for protein-protein interactions and signal-responsive
transcriptional regulation that is essential for cytoskeletal organization and SMC
differentiation 25,26,27,28. The discovery of the myocardin (Myocd) family of SRF-
dependent transcriptional coactivators was a critically important step toward understanding
how SMC-selective gene transcription is achieved by combinatorial interactions with the
more widely expressed DNA binding protein SRF (Srf) 29,30,31,32,33,34,35,36,37. The
identification of transcriptional corepressors and chromatin-associated silencers of SRF/
myocardin-dependent gene expression is particularly important for characterization of
mechanisms by which SMC progenitors are formed and maintained in vivo 38,12,39. The
combinatorial nature of SMC selective transcription provides for rapid and versatile control
of SMC phenotype in response to a multitude of environmental cues 29,40. An additional
component of SMC identity that is not well characterized is cell type-specific alternative
splicing. For example, myocardin is alternatively spliced into two forms; a long form (935
amino acids) that is selectively expressed in cardiac muscle and contains a Mef2-interacting
domain and a short form (856 amino acids) that lacks a Mef2 binding motif and is SMC-
specific 41. Further work shows that the SMC isoform of myocardin synergistically interacts
with Nkx3.1 (Nkx3-1, bagpipe) whereas the cardiac isoform of myocardin does not 42.
Vascular SMC-selective alternative splicing has also been reported for α-tropomyosin,
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metavinculin, smoothelin, and Ca(v)1.2 calcium channel α-subunit. SMC progenitors may
also be maintained as such by covalent modifications of either SRF or myocardin. For
example, phosphorylation of Ser162 in the MADS domain inhibits DNA binding and
transcriptional activity of SRF 28. Moreover, sumoylation of myocardin at Arg445 in a
PIAS1-dependent manner was shown to be an activating modification for SRF-mediated
myogenesis 43. In addition, myocardin proteins contain a B-box domain similar to that found
in Elk1. Competitive binding to SRF via these related B-box domains shifts in favor of Elk1
when growth factors stimulate the MAP kinase pathway and toward myocardin as growth
factor stimulation diminishes 44.
Origins of Vascular Smooth Muscle Progenitors—Over the last three decades, fate-
mapping studies have identified at least 8 independent origins for vascular SMC
progenitors 4,5,45,46. Each of these progenitors has a distinctly different lineage history, yet
each produces a similar cell type that transcribes a common set of SMC marker genes
(SMαActin (Acta2), SM22α (Tagln), SM-calponin (Cnn1), SM-MHC (Myh11) upon
differentiation. How progenitor cells from such different developmental origins become
specified for a common smooth muscle fate, and how they are maintained as smooth muscle
myoblasts during the migration, proliferation and heterotypic cell-cell interactions required
to position them for differentiation around nascent blood vessels is not known (Figure 1).
Moreover, in perinatal and adult vessels recent evidence suggests that SMC progenitor cells
reside in a privileged signaling domain or niche environment within the tunica
adventitia 6,8,9 (Figure 2). Their persistence in this perivascular location throughout adult
life suggests that cells and matrix components of the adventitial niche provide important
signals that maintain the progenitor phenotype and prevent premature SMC
differentiation 9,47. Maintenance of SMC progenitors requires transcriptional silencing of
SRF-dependent SMC differentiation marker genes within these different environments.
Current evidence suggests two types of pathways function coordinately to prevent premature
SMC differentiation and thereby allow for the cell migration and cell division events
required to position and expand SMC progenitor cell pools during vessel wall growth and
repair. One pathway acts at the level of regional chromatin structure to limit access of SRF
and its coactivators to critical paired CArG box elements found in most SMC marker
genes 12,48,49,50. A second pathway acts at the level of SRF bound to CArG sequences in
SMC target genes to silence gene transcription that would otherwise be activated by the
occupancy of SRF and one or more SRF coactivators on SMC gene targets 39,44,51,52.
Epigenetic Controls of Smooth Muscle Differentiation—Genomic DNA is
organized into repeating units called nucleosomes consisting of histone octamers wrapped
twice by stretches of DNA each an average of 146 bp in length. This compacts genomic
DNA about sevenfold 53,54. Eukaryotic gene transcription, however, takes place in the
context of nucleosomal DNA that is further compacted into higher-ordered structures
collectively known as chromatin. Chromatin is highly dynamic and organized into
chromosomal domains that adopt specific conformations and positions within the overall
three dimensional structure of the nucleus 55. Reversible covalent modifications of histone
tail residues by acetylation, methylation, phosphorylation and ubiquitination or histone tail
proteolytic cleavage play critical roles in the control of eukaryotic gene expression and cell
fate by modifying accessibility of the chromatin-associated DNA template to sequence-
specific DNA binding proteins 56,57,58. Collectively, covalent histone tail modifications
together with ATP-dependent DNA conformation-modifying enzymes produce an
epigenetic landscape that, to a large extent, determines what genes are available to the
general transcriptional machinery for gene expression 54. Essentially all genes, including
SRF-dependent SMC differentiation marker genes, operate within this complex three-
dimensional network of higher-ordered chromatin structure.
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With respect to SRF-DNA interactions in SMCs and their progenitors, current evidence
suggests that CArG box elements are more accessible for SRF binding in SMCs than the
same DNA sequences are in non-SMCs 59. This would help to explain why SMC marker
genes are silent in non-SMCs that nonetheless express SRF together with one or more
myocardin-related transcription factors (MRTFs) 30 or other known SRF
coactivators 60,61,62,63,64. The covalent modifications of specific histone residues (called
histone marks) in SMC compared to non-SMCs are complex (reviewed in 49). In principle,
histone acetylation on lysine residues is rapid and reversible and correlates with ongoing
rates of gene transcription. The addition of negatively charged acetyl groups is thought to
disrupt histone protein-DNA interactions effectively relaxing chromatin structure and
thereby enabling increased transcription factor access to binding sites on DNA.
Counteracting this activating histone modification is a family of histone deacetylases
(HDACs) that catalyze the removal of histone acetyl groups and inhibit gene
transcription 65. Recruitment of SRF to CArG elements in SMC promoter/enhancer regions
closely correlates with acetylation of lysine residues on histones H3 and H4 59,66,67. Histone
acetylation at these loci may be catalyzed by the ability of myocardin to bind and recruit
histone acetyltransferases, such as P300 (Ep300) 38,68. Further evidence that transcription of
SMC marker genes is enhanced by histone acetylation is the finding that treatment of SMCs
with trichostatin A, an HDAC inhibitor, increased endogenous SM22α (Tagln) gene
expression in vitro 67. Histone lysine residues can also be methylated 69. A well-
characterized methylation of histone H3 at lysine 9 (H3K9) is associated with gene
silencing. Like histone acetylation, histone methylation is also reversible. A family of
jumonji domain-containing histone demethylases that catalyze the removal of methyl groups
from specific histone lysine residues has been identified 70,71. Indeed, Lockman et al
reported that the jumonji domain-containing H3K9 histone demethylase, Jmjd1a/JHDM2a,
is an MRTF-A (Mkl1) interacting protein that stimulates SMC marker gene expression by
demethylating H3K9 residues in SMC target genes 72. Therefore, pathways that control the
type and extent of covalent histone modifications on intact chromatin surrounding SMC
differentiation target genes are clearly important to identify in future studies to better
understand how SMC progenitor cells are formed and maintained in vivo.
Of particular interest for the focus of this review are epigenetic changes found in SMC
progenitors that are not found when compared to differentiated SMCs or to progenitors of
non-SMC lineages. One promising epigenetic modification that correlates with smooth
muscle identity was reported by McDonald et al 59 using an A404 clonal cell line derived
from the multipotential teratocarcinoma cell line P19. In the presence of retinoic acid, A404
cells rapidly adopt a SMC phenotype including expression of SM-MHC (Myh11) 66.
Employing CArG box mutants in the SMα-actin (Acta2) promoter that cannot bind SRF,
McDonald et al showed that failure of SRF binding to DNA led to pronounced decreases in
H3K9 acetylation and H3K79 dimethylation most likely because these histone modifications
are added to SMC chromatin after SRF binding and transcriptional activation 59. By
contrast, H3K4 dimethylation (H3K4me2) was unaffected by the presence or absence of
SRF bound to SMα-actin (Acta2) promoter CArG box elements 59. Moreover, chromatin
immunoprecipitation (ChIP) assays showed that SRF-myocardin complexes that activate
transcription physically associate with H3K4me2 whereas transcription silencing SRF-Elk1
complexes do not. Finally, in the presence of PDGF-BB, a stimulus known to downregulate
mature SMC marker gene expression, reductions in SRF bound to H3K4me2 were found 59.
These results suggest that H3K4me2 is an epigenetic histone mark that may be an important
element of a molecular profile that confers SMC identity onto a progenitor cell.
If true, histone methyltransferases responsible for the dimethyl modification of H3K4 would
be key targets of one or more pathways that confer SMC specification on a multipotential
progenitor cell in vivo. There are at least two well-characterized classes of histone
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methyltransferases with this activity, the mixed lineage leukemia (MLL) family and SET1
family 73,74. But these histone methyltransferase enzymes are widely expressed and are not
smooth muscle lineage specific. Moreover, they do not possess intrinsic specificity for
histone residues on smooth muscle marker chromatin as opposed to chromatin anywhere
else in the genome. This suggests that there must be more specific guidance cues that recruit
histone methyltransferase-containing complexes to smooth muscle gene targets in progenitor
cells. Preliminary findings raise the interesting possibility that a previously identified DNA
binding homeodomain protein that associates with SRF and recruits histone
acetyltransferase activity to SMC target genes, known as Pitx2 75,76, serves to guide MLL-
type histone methyltransferases to SMC target genes 77. While clearly an important
objective, identification of these molecular guidance cues for placement of critical histone
methyl marks on SMC target gene loci in SMC progenitor cells still leaves open the question
of how gene targets so marked are maintained in a transcriptionally silent state until an
appropriate time during embryonic development or adult homeostasis for SMC
differentiation.
In addition to histone modifications, chromatin structure is also controlled by a family of
ATPase-dependent chromatin remodeling enzymes that are key components of the SWI/
SNF complex 78. In vertebrates, the two major ATPase subunits of the SWI/SNF complex
are Brahma (Brm1) and Brahma-related gene 1 (Brg1). Zhang et al reported that the
myocardin family member, MRTFA (Mkl1, Mal), recruits Brg1 to SRF-dependent SMC
marker gene targets to promote gene transcription 50. The SW13 cell line, deficient in both
Brg1 and Brm1, was unable to support MRTFA-mediated increases in SRF-dependent SMC
marker gene activity 50. Chromatin immunoprecipitation (ChIP) assays showed that
dominant negative forms of Brg1 strongly inhibited the MRTFA-enhanced SRF binding to
promoter regions of SMC marker genes without affecting SRF binding to CArG elements in
immediate early genes such as c-fos. Similar results were reported for effects of Brg1
interaction with myocardin (Myocd) on SMC target gene expression 79. Therefore
mechanisms to limit the expression or function of ATPase-dependent chromatin remodeling
complexes at SMC differentiation marker genes may be important elements in the
maintenance of transcriptional silencing in SMC progenitor cells.
Silencing of SMC Differentiation Marker Genes in SMC Progenitors—When
considering how SMC progenitors are formed and maintained, it is important to realize that
SRF and CArG box chromatin interacts not only with potent coactivators like myocardin but
also with potent transcriptional silencer complexes as well 39,80. For example, the muscle
segment homeobox proteins (Msx1 and Msx2) form ternary complexes with SRF (Srf) and
myocardin (Myocd) that block DNA binding of the SRF-myocardin complex to CArG box
motifs in SMC marker genes 80. Another example is KLF4 (Klf4), a zinc finger protein 81
that binds to conserved GC-rich elements located near paired CArG boxes in the SMα-actin
(Acat2) promoter and other SMC marker genes 82. Klf4 physically binds to SRF, recruits
HDAC2 (Hdac2) and HDAC5 (Hdac5) to SMC marker genes, and blocks SRF association
with CArG box sequences in intact chromatin 52. The forkhead transcription factor FoxO4
(Foxo4) physically interacts with myocardin and inhibits its SRF-coactivator function thus
acting as a repressor for SMC differentiation 51. In response to signals that activate the PI3-
kinase/Akt pathway, Foxo4 is exported from the nucleus, and SMC differentiation target
genes become transcriptionally active. The co-repressors Msx1, Klf4 and Foxo4 were found
to be coexpressed with SRF and myocardin in SMC progenitor cells obtained from neonatal
aortic adventitia 9. More recently, the HMG box-containing protein HMG2L1 was shown to
physically interact with myocardin and abolish the binding of myocardin-SRF complexes to
CArG box elements in SMC promoters. Overexpression of HMG2L1 in SMCs repressed
SMC marker gene expression whereas depletion of endogenous HMG2L1 increased
expression of the same SMC marker genes 83.
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PRISM (PR domain in smooth muscle) (Prdm6) is a PR and SET domain-containing protein
with transcriptional repressor activity that is selectively expressed in smooth muscle
tissues 84. It is expressed as early as E11.5 in the aortic wall corresponding to initial events
in tunica media formation 84. It is also expressed in developing airway, tracheal and bladder
smooth muscle. PRISM is capable of recruiting histone methyltransferases and other
chromatin remodeling enzymes including class I HDACs through interactions of these
factors with its PR domain and thereby mediate transcriptional repression in SMC
progenitors. Among the gene targets whose expression in SMCs is repressed by PRISM are
Gata6 and myocardin (Myocd). Indeed, siRNA-mediated knockdown of PRISM produced a
concomitant induction of SMC differentiation marker genes, including SM-MHC,
suggesting some level of constitutive repressor activity is maintained by PRISM in
differentiated SMCs. Other members of the PR/SET domain family are reported to play
important roles in the specification of neural crest progenitors 85 and slow-twitch skeletal
muscle fibers 86.
Control of cell differentiation by transcriptional corepressors plays important roles in
progenitor cell maintenance in skeletal muscle and other progenitor cell types 87. For
example, skeletal muscle myoblasts are maintained, in part, by a MEF2-dependent
corepressor complex that normally silences muscle-specific gene expression 88. This
complex consists of MEF2 (Mef2), MITR (Mef2-interacting transcriptional repressor), HP1
(heterochromatin interacting protein-1), Hdac4 and Hdac5 89. Activation of calcium/
calmodulin-dependent protein kinase leads to phosphorylation of Hdac4 and Hdac5 resulting
in nuclear export of these transcriptional repressors 90. The Mef2 released from
phosphorylated HDACs associates with MyoD (Myod1) and E-protein heterodimers
resulting in transcriptional activation of skeletal muscle structural genes. Mef2, like Srf, is a
MADS box-containing DNA binding protein that provides a platform for protein-protein
interactions in skeletal myoblasts. Another important class of negative transcriptional
regulators is the Groucho/TLE gene family, which consists of four unlinked genes named
TLE1-4 in humans and Grg1-4 in mouse 91. Grg/TLE proteins interact with engrailed
homology-1 (EH1) domain-containing DNA binding proteins and recruit class II HDACs to
chromatin via a glycine and proline-rich domain in the N-terminal half of Grg/TLE
proteins 92. EH1 domain proteins important in vascular development include the forkhead
box transcription factors of the FoxA, FoxC and FoxD families, T-box proteins, and muscle-
segment homeobox proteins of the Msx family 93.
Roles for Noncoding RNA in Formation and Fate of SMC Progenitors—A
growing number of studies now indicate the important roles played by noncoding
RNAs 94,95 in development and differentiation of vascular smooth muscle 96. For example,
maintenance of fully differentiated phenotypes of vascular SMCs is dependent on expression
of microRNA-143 (miR-143) and miR-145 97,98,99,100,101. miRNAs are a class of ∼ 22-
nucleotide noncoding small RNAs that play essential roles in regulating gene expression by
posttranscriptional mechanisms including arrest of translation and degradation of
mRNAs 95. Loss of function for miR-143/145 results in arteries with thinner walls and
SMCs with a noticeable lack of differentiated features. Systemic blood pressure and smooth
muscle contractile activity are reduced in miR-143/145-deficient mice 100, as is the ability to
migrate due to disarray of actin stress fibers 99. Expression of miR-145 alone was sufficient
to convert multipotent neural crest cells into vascular SMCs suggesting that miR-145 targets
are important for maintaining the SMC progenitor phenotype in the neural crest lineage 97.
Likewise, overexpression of miR-145 was able to substantially rescue the vascular SMC
defects resulting from the loss of dicer, an endonuclease required for miRNA synthesis 95, in
SMCs 102. Identified targets of miR-143/145 include two gene products that are known
repressors of SRF-myocardin-induced transcription, namely Elk1 and Klf4, as well as the
potent SRF coactivator MRTF-B (Mkl2) 97,99. In addition, miR-145 has been shown to
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downregulate expression of Klf5, a factor associated with repression of the mature
differentiated SMC phenotype 99,101. Conversely, miR-221 and miR-222 down-regulate
factors that promote expression of the differentiated SMC phenotype thus leading to
dedifferentiation of SMCs 103,104. These two miRNAs are induced by PDGF-BB and target
myocardin (Myocd) transcripts for down-regulation 104.
Recent studies suggest the paradoxical idea that gene silencing requires transcription
initiation 105. Thus, current evidence suggests that long noncoding RNA molecules
(lncRNAs) recruit transcriptional repressors to specific sites in the genome to silence gene
expression. For example, mammalian X chromosome-inactivation requires noncoding Xist
RNA that forms a hairpin structure that recruits polycomb group repressor complexes
(PRC2) to the X inactivation center to silence gene transcription 106,107. Likewise, a
noncoding RNA transcript from the INK4b/ARF locus directs repression of that locus by
recruiting PRC2 silencer complexes 108. Most promoters are now known to produce short
transcripts in both 5′ and 3′ orientations that encompass CpG islands frequently found in
promoter regions 109. Short hairpin structures produced by these non-coding transcripts
recruit PRC2 repressor complexes that spread across a local region of DNA, catalyze
trimethylation of histone H3K27 (H3K27me3) and silence gene expression. Activation of
transcription from this repressed locus requires demethylation of H3K27me3 by histone
demethylase activity 110. As discussed above, expression of a jumonji domain-containing
H3K9 histone demethylase, Jmjd1a/JHDM2a, in SMCs is associated with transcriptional
upregulation of smooth muscle differentiation marker gene expression 72. More recently a
positive role for lncRNAs acting as transcriptional enhancers was reported suggesting that
regulatory functions for this important class of noncoding RNAs will likely turn out to be
complex and interesting 111. A role for lncRNAs in control of cell fate in general, and SMC
fate in particular, is an important area for future work.
Signal-Responsive Differentiation of SMC Progenitors—As discussed above, SMC
progenitor cells are poised to differentiate to SMCs but are restrained from doing so by
redundantly acting repressor/silencer mechanisms. Reductions in the activity of SRF-
dependent corepressor complexes or increases in the activity of SRF-dependent coactivator
complexes are sufficient to trigger SMC differentiation in these cells. A principle pathway
for formation of SRF-coactivator complexes involves extracellular signal-dependent
activation of RhoA-GTPase (Rhoa) and its downstream effectors Rho kinase (Rock1), LIM
kinase (Limk1), protein kinase N (Pkn1), and mammalian diaphanous (mDia) proteins.
Activation of Rock1 and Limk1-dependent signaling leads to actin polymerization, stress
fiber formation and cytoskeletal reorganization 112,113,114. Activated Rock1 is reported to
translocate to the nucleus, phosphorylate P300 and promote SMC gene
transcription 115,116,117. Of particular importance was the finding by Treisman's group that
Rhoa- GTPase-mediated actin treadmilling, specifically the polymerization of G-actin to F-
actin, results in the mobilization of potent SRF coactivators MAL/MRTFs/MKLs from
inhibitory binding sites on G actin followed by their translocation to the nucleus 32,118,119.
Accumulation of MRTFs in the nucleus and their partnering with SRF and other
coactivators 60,61,62,63,64 leads to transcriptional activation of SMC target genes and SMC
differentiation by mechanisms discussed above. It is reasonable to assume that in actively
migrating SMC progenitors, repetitive actin filament turnover during extension of
lamellipodial and filopodial projections constantly regenerates cytoplasmic G actin and
maintains nuclear MRTF activities at low levels. Once these cells reach their destination and
take up positions in developing tunica media, F-actin predominates and MRTFs are found in
their active nuclear forms. This mechanism would couple morphogenesis of blood vessel
walls with differentiation of a major constituent cell type (SMC) present within those walls.
For example, conditional deletion of integrin-linked kinase (Ilk) produces overactive Rhoa
and Rock1-mediated signaling in SMC progenitors resulting in dermal arterioles with
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smaller diameters and loss of circumferential SMC alignment consistent with premature
differentiation, excessive contraction and lack of proliferative expansion of SMC progenitor
pools 120. These findings reinforce the idea that SMC progenitor pool sizes are critical
determinants of blood vessel size, length, and function. The relative state of cytoskeletal
actin polymerization, and thus levels of active MRTFs, depends upon Rhoa-GTPase-
mediated signaling pathways that respond to factors present in the local environment thus
emphasizing the importance of niche-dependent signaling for the maintenance of a SMC
progenitor phenotype 9,47.
Smooth Muscle Progenitors and the Embryonic Vascular System—Genetic
approaches to developmental fate mapping reveal the intricate diversity of vascular SMC
lineages in development, but they leave us wondering how progenitor cells of such diverse
embryonic origins and developmental histories can differentiate into a common cell
type 4,5,46. For example, the dorsal surface of the neural tube contains progenitor cells that
migrate into the pharyngeal arch complex between E8.5 and E9.5 and produce SMCs that
form the walls of the great arteries 45,121,122,123. Clonal analysis ex vivo shows that
individual neural crest progenitor cells are multipotent 124,125. Thus factors in the
environment through which these cells migrate play essential roles in specifying their
fate 126,127,128. SMCs in the descending aorta originate from progenitors in epithelial
somites that express Pax3 and FoxC2 5,129,130. SMC fate specification occurs when
expression levels of FoxC2 exceed those of the promyogenic factor Pax3 130 and since
FoxC2 represses transcription of Pax3, a SMC fate is stabilized over the alternative skeletal
muscle fate. The abundance ratio of FoxC2 and Pax3 is controlled by signals in the somite
microenvironment 130 and thus resembles SMC fate specification in cardiac neural crest
progenitors during delamination and migration from the neural tube. A likely scenario based
on current data (Figure 1) is that SMC progenitor cells thus specified make contact with
endothelial cells 131, engage notch-dependent signaling pathways 132,133,134,135,136,
mobilize MRTF-B (Mkl2), and initiate SMC differentiation 137,138. It is important to point
out that the requirement for MRTF-B (Mkl2) is restricted to cardiac neural crest-derived
SMCs indicating that SMC progenitors originating from other sources in the embryo must
have different molecular requirements for SMC differentiation even though the same SMC
differentiation marker genes are activated in all cases 137,138. Indeed, analysis of MRTF-A
(Mkl1, Mal)-deficient mice revealed that neural crest-derived vascular SMCs differentiated
normally whereas myoepithelial cells of mammary gland ductal tissues failed to develop a
contractile phenotype 139.
SMCs in the coronary vasculature arise from a separate population of embryonic
progenitors. The majority of coronary SMCs (CoSMCs) can be traced back to origins in the
proepicardium (PE), a transient collection of mesothelial cells that appears at the sinoatrial
junction at about E8.5 in the mouse 140,141,142. Specification of lateral plate mesoderm for a
proepicardial fate is mediated by an antagonistic interplay between BMP and FGF
signaling 143,144. In avian embryos, soluble factors produced by the developing liver bud,
but not lung bud, direct multipotent mesoderm progenitors to adopt a proepicardial
identity 145. In zebrafish embryos, an early role for Tbx5 in specifying PE progenitor cells
was identified that results in competence to respond to BMP4 (Bmp4) released by the
developing myocardium 146. PE cells thus specified reach the heart around E9.5 in the
mouse and grow out over the surface of the myocardium to form a single layer of epicardial
cells. Then around E13.5 to E14.5 some epicardial cells undergo an epithelial to
mesenchymal transition (EMT), loose their epicardial phenotype and adopt a pre-SMC
phenotype in the subepicardium in vivo 142,147,148,149. Epicardial cell EMT is associated
with a Rhoa-GTPase and Rock1-mediated cytoskeletal actin reorganization that is required
for CoSMC differentiation 115,150. Epicardial cells from adult hearts appear to retain their
specification to differentiate into CoSMCs, at least in vitro 151. Maintenance of a CoSMC
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progenitor phenotype in the epicardium may be due, in part, to high levels of epicardial
expression of EH1 domain-containing T-box proteins including Tbx5 and Tbx18 152,153,154.
In addition to cardiac neural crest and proepicardium, a third distinct source of SMC
progenitor cells in the early embryo is found in an Islet-1 (Isl1)-positive cell population that
contributes multiple lineages to the developing heart 155. Isl1 is a LIM-homeobox
transcription factor that marks the second heart field of cardiac progenitors and is required
for formation of the atria, right ventricle, and cardiac outflow tract 156. Genetic fate mapping
studies using Isl1-cre to mark early cardiac progenitor cells in the mouse showed that SMCs
in the walls of the aortic root, pulmonary trunk and coronary stems are produced from Isl1-
positive progenitors that are distinct from progenitors in the cardiac neural crest. Also
labeled by Isl1-cre were endothelial cells, endocardial cells, and myocardial cells of the right
ventricle suggesting that the progenitor population is multipotential 155. Clonal analysis of
Isl1+ progenitor cells verified their unique multilineage potential 155,157. Similar results
were reported by Kattman et al who isolated VEGF-R2/Flk1-positive progenitor cells from
head-fold stage mouse embryos and showed that single progenitor cells generated colonies
that contained cardiac myocytes, endothelial cells and vascular SMCs thus confirming their
multilineage potential 158.
Smooth Muscle Progenitors and the Adult Vascular System—Pericytes are
smooth muscle-like microvascular mural cells with progenitor-like properties (Figure 2).
Proper investment of microvessel walls with pericytes is a required step in vascular
development and angiogenesis 159,160. However, little is known about the developmental
origins of pericytes as very few lineage-mapping studies have addressed whether or not
pericytes share common origins in the embryo with vascular SMCs. One exception to this is
in the brain where pericytes and cerebral vascular SMCs have been shown to originate from
cephalic neural crest progenitor cells 161. Many pericytes exhibit the potential for
multilineage mesenchymal cell differentiation 162,163. Pericytes are classically defined as
cells embedded underneath the basal lamina of microvascular endothelial cells. This position
is strikingly similar to that of muscle stem cells known as satellite cells that reside under the
basal lamina of skeletal muscle myofibers. In both cases, the position of resident pericytes
and satellite cells under a basal lamina may be important to efficiently receive signals
released from endothelial cells or myofibers respectively that maintain their progenitor
phenotypes. Cossu and coworkers have shown that pericytes isolated from injured skeletal
muscle tissue and injected intra-arterially have the remarkable ability to home to injured
skeletal muscle, reconstitute satellite cell pools, form skeletal muscle myofibers, and
promote muscle regeneration in vivo 164,165,166. This property may reflect an origin of some
pericytes from mesoangioblasts, a population of multipotential mesenchymal progenitor
cells that appear early in vascular development as VEGFR2/Flk1-positive cells associated
with the abluminal side of the dorsal aorta 167.
The possibility that vascular SMC progenitor cells reside in the outer layer of artery wall,
the adventitia and associated perivascular tissues, has been suggested several times over the
years (Figure 2) 168,169. For most investigators, these suggestions were regarded as
anecdotal and data consistent with a role for the adventitia as harboring vascular progenitor
cells was largely ignored. However, in a survey of adult vessels in ApoE-/- mice, Hu et al
reported finding SMC marker-negative, stem cell antigen-1 (Sca1; Ly6a)pos progenitor cells
in the adventitia of large arteries 6. When isolated from genetically-marked animals and put
back on the adventitial side of vein grafts, adventitia-derived Sca1pos cells were found in the
media at 2 weeks and in the neointima at 4 weeks after transplantation where they no longer
expressed Sca1 and became immunopositive for SMC differentiation markers 6. Similarly, a
population of CD34pos/PECAM1neg cells was found in human internal thoracic artery with a
capacity to form capillary-like microvessels in ex vivo aortic ring assays 7. The
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concentration of these cells in the inner adventitia led Zengin et al to refer to this location as
a “vasculogenic zone” in the artery wall 7. More recently, a novel domain of sonic hedgehog
(Shh) signaling was described that is restricted almost entirely to the adventitia of large and
medium-sized arteries and veins, and colocalizes with the vasculogenic zone described by
Zengin et al 9. Within this Shh signaling domain a population of Sca1pos/CD34pos progenitor
cells was found with the capacity to differentiate into mural cells (pericytes and SMCs) in
vitro and promote angiogenesis in matrigel implants in vivo 9. Another factor implicated in
an adventitial microenvironment for SMC progenitors is stromal cell-derived factor 1-alpha
(SDF-1α; Cxcl12) 170. SMC-specific deletion of PTEN (Pten), a dual-specificity lipid and
protein phosphatase, increased production of SDF-1α by Pten-deficient SMCs and resulted
in accumulation of CXCR4-positive circulating progenitor cells in a perivascular, adventitial
location 170. These reports are particularly interesting in light of past studies that suggest
roles for adventitial cells in artery wall thickening in pulmonary hypertension 8 and in
neointimal formation after vascular injury 168. For example, animals exposed to chronic
hypoxia develop markedly thickened pulmonary artery walls (reviewed in 8). This form of
hypertensive remodeling is characterized by additional layers of smooth muscle forming on
the adventitial side of the pulmonary artery wall and may well consist of SMCs that
originate from local progenitors resident in the adventitia 8. Likewise, mice that are
haploinsufficient for tropoelastin (Eln) exhibit additional layers of SMCs and elastin that
form on the adventitial side of the aorta during late stages of embryogenesis around E16.5 to
postnatal day 3 171,172. Whether SMC progenitor cells in the adventitia can detect
mechanical stretch of the artery wall, or changes in relative hypoxia, or respond to soluble
signals associated with wall remodeling stimuli are important questions for future studies.
Experiments to determine if circulating progenitor cells of bone marrow origin contribute
intimal SMCs to atherosclerotic plaques were initially interpreted as supporting such an
origin 173,174. In those early studies, up to 50% of intimal SMCs within mouse
atherosclerotic plaques were reported to be derived from progenitors of bone marrow
origin 174. However, as work progressed on this possibility, an origin for intimal SMCs from
marrow-derived progenitors seemed less likely 175,176. A large influx of marrow-derived
inflammatory cells, mostly monocytes and macrophages, occurs early in lesion formation.
High-resolution confocal imaging is required to determine if the marker used to detect cells
of bone marrow origin is actually coexpressed with markers used to identify intimal
SMCs 175. This is not trivial as intimal SMCs and inflammatory cells are often in very close
proximity, if not actual physical contact, during these early time points. In addition, common
methods for marrow-derived mononuclear cell isolation lead to their contamination with
platelet membrane fragments (microparticles, MPs) carrying markers used to identify other
cell types (e.g, CD31, endothelial cells)177. By extrapolation, inflammatory cell MPs may be
shed and incorporated into nearby SMCs leading to false conclusions about their origins.
Upon extending the time course of experiments out to 16 weeks after wire injury to femoral
artery, Daniel et al clearly showed that bone marrow-derived cells of any type were
dramatically reduced in numbers while intimal cells expressing smooth muscle markers
continued to increase 176. By 16 weeks after injury there were very few, if any, cells that
coexpressed the bone marrow lineage marker and SMC specific proteins. Taken together,
the current data suggests that inflammatory cells contribute an early paracrine activity that
diminishes greatly with time, and that there is little, if any, long-term contribution of
marrow-derived progenitor cells to the vascular SMC population in these vessels.
Myofibroblasts are derived from resident tissue fibroblasts and are found in abundance in a
number of different reactive and pathogenic conditions 178. Myofibroblasts are present in
granulation tissue during wound healing, in connective tissue stroma surrounding solid
tumors, and are abundant in fibrotic tissue. Because myofibroblasts express some of the
commonly used SMC markers, such as SMα-actin (Acta2) and SM22α (Tagln) it is
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frequently assumed that these cells are SMC progenitors that can go on to complete a
differentiation sequence and become SMCs. In fact, although SMCs and myofibroblasts
both express the SMα-actin (Acta2) gene, they use distinct molecular mechanisms to do
so 77. For example, analysis of MCAT element mutations in the SMα-actin promoter/
enhancer in transgenic mice showed that myofibroblasts within granulation tissue of skin
wounds required intact MCAT elements for reporter gene expression whereas vascular
SMCs as well as SMCs of the stomach, bladder and intestine did not 77. Moreover, different
TEF-1 (Tead1) family members associate with MCAT elements in myofibroblasts (RTEF-1;
Tead4) compared to SMCs (TEF-1; Tead1) 77. In addition, myofibroblasts differ from SMCs
in an absence of expression of smoothelins, relatively late stage differentiation markers for
SMCs 178,179. Thus activation of SMC markers in myofibroblasts occurs by distinct
molecular pathways compared to SMCs, arguing that resident tissue fibroblasts or
myofibroblasts are not SMC progenitors under most conditions.
Summary
The number of different smooth muscle types far exceeds that of skeletal or cardiac muscle.
This diversity reflects a multiplicity of different kinds of SMC progenitors found in
embryonic and adult tissues. It also reflects the versatility of a common molecular mediator
for SMC differentiation, a complex of SRF and a myocardin family member occupying one
or more CArG box cis-elements. Through interactions with a large number of co-activators
and co-repressors that recruit epigenetic regulators of regional chromatin structure, this core
transcription module is made responsive to a wide variety of extracellular signaling cues that
specify and direct cell fate. Maintenance of SMC progenitor pools requires signals that
allow for proliferative expansion during tissue growth or repair together with activation of
redundant transcriptional silencing mechanisms to maintain the SMC progenitor phenotype
and prevent SMC differentiation. A more complete understanding of the identity of these
signals and the molecular mechanisms that are utilized to form and maintain vascular SMC
progenitor cells will enable advances in somatic cell reprogramming and stem cell biology
to be more effectively applied to disorders of the vessel wall.
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Non-standard Abbreviations and Acronyms
ACLP aortic carboxypeptidase-like protein
APEG aorta preferentially-expressed gene
BMP bone morphogenic protein
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CoSMC coronary smooth muscle cell
En embryonic day n
ECM extracellular matrix
Flk1 fetal liver kinase-1
H3K4me2 histone H3 lysine-4 dimethyl modified
HAT histone acetyltransferase
HDAC histone deacetylase




MLL mixed lineage leukemia
MRTF myocardin-related transcription factor
PIAS1 protein inhibitor of activated STAT-1
PRC2 polycomb group repressor complex 2
Rock1 rho kinase-1
SCA1 stem cell antigen-1
siRNA small interfering RNA
SMC smooth muscle cell
SRF serum response factor
VEGF-R2 vascular endothelial cell growth factor receptor-2
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Figure 1. Development of vascular smooth muscle from embryonic progenitors
(a) Vasculogenesis: Vascular development begins when angioblasts differentiate into
endothelial cells (red) that self-assemble into a nascent capillary-like vascular network. (b)
Investment: Increasing cardiac output from the developing heart stimulates production of
mesenchymal cell chemoattractants by endothelial cells. SMC progenitors (brown) begin to
invest the vessel wall around E10.5 in the mouse. Close contact with endothelial cells
initiates SMC differentiation (blue cells). The position of the vessel within the embryo
determines what type of SMC progenitor will be involved in producing the tunica media.
Proliferation of SMC progenitor cells is required to supply numbers of SMCs sufficient for
continued vascular development. (c) Differentiation and maturation: As layers of SMCs are
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added to the developing artery wall, a cross-linked extracellular matrix is formed that
defines the structure of the mature tunica media.
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Figure 2. Sources of vascular smooth muscle progenitor cells in adults
In large arteries (red) and veins (grey), resident SMC progenitors have been identified in the
adventitial layer (green cell clusters) 6,7,9 and in the medial layer (scattered blue cells) 180.
Some reports suggest that SMCs in atherosclerotic plaques and intimal masses can arise
from circulating, bone marrow-derived progenitor cells (yellow) 173,174 while others report
finding no evidence to support that possible origin 175,176. In microvessels, pericytes
(purple) have been proposed to have multilineage differentiation potentials 162,166, and can
act as SMC progenitor cells 159,163.
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